Adevinta ASA DR (OTC:ADEVY) Stock, Quote.Headers.trade-ideas

Adevinta ASA DR

General

KNDI

Kandi Technologies Announces Availability Of Its Products On Academy Sports + Outdoors Online Store

<p>Dynagas LNG Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLNG#NYSE">DLNG</a>) reported quarterly earnings of $0.25 per share which missed the analyst consensus estimate of $0.28 by 10.71 percent.  The company reported quarterly sales of $37.615 million which missed the analyst consensus estimate of $37.915 million by 0.79 percent.  This is a 0.10 percent decrease over sales of $37.653 million the same period last year.</p>


Earnings

Earnings Misses

News

DLNG

Dynagas LNG Partners Q2 2024 Adj. EPS $0.25 Misses $0.28 Estimate, Sales $37.615M Miss $37.915M Estimate

Macro Economic Events

Commodities

Economics

Markets

Dow Jones: OPEC Trims Oil Demand Outlook Further Amid Price Slump

<p>VCI Global Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCIG#NASDAQ">VCIG</a>) (Frankfurt: H0T) ("VCI Global," "VCIG," or the "Company") is pleased to announce its planning related to the reorganization of its AI business, capital raising, and the forthcoming share repurchase program.<br /><br />&nbsp;</p>
<p>AI Business</p>
<p>VCIG has initiated a strategic reorganization of its AI operations under the newly formed subsidiary, VC AI Limited. The AI business has been restructured into four pivotal business segments:</p>
<ul>
<li>GPU servers – VCIG will launch its proprietary brand of GPU servers for the AI industry and commence operation in October 2024.</li>
<li>GPU cloud computing – The Company will debut its AI data center business by launching AI Computing Center in Malaysia ("AICC Malaysia"), with GPU cloud computing services scheduled to commence in the second quarter of 2025, as previously announced.</li>
<li>AI and large language model (LLM) solutions – VCIG has also made notable advancements in its AI and LLM solutions capabilities, which are now actively offered to clients.</li>
<li>Cybersecurity – The Company continues to enhance its cybersecurity solutions, focusing on wider and more sophisticated offerings within the AI space.</li>
</ul>
<p>Capital Raising</p>
<p>The capital-raising round for the AI business has been successfully concluded, and the initial funding needed for this business has been secured. The Company is now poised to implement its growth strategy.</p>
<p>Share Repurchase Program</p>
<p>In alignment with its strategic objectives, VCIG intends to initiate a previously announced share repurchase program in the first quarter of 2025. This program is designed to augment shareholder value and reinforce its commitment to sustained long-term growth.</p>
<p>"VCI Global is committed to driving long-term shareholder value through our pioneering AI businesses. Our advancements in these areas are strategically positioned to capitalize on Southeast Asia's growing digital economy. We look forward to the execution of our growth plan and share repurchase program, which underscore our dedication to sustainable growth and enhancing shareholder returns," said Dato' Victor Hoo, Group Executive Chairman and Chief Executive Officer of VCI Global.</p>


Buybacks

VCIG

VCI Global Provides Updates On Its AI Business; The Capital-Raising Round For The Ai Business Has Been Successfully Concluded, And Intends To Initiate A Previously Announced Share Repurchase Program In Q1 2025

<p>Across the recent three months, 30 analysts have shared their insights on Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">11</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $417.37, a high estimate of $505.00, and a low estimate of $300.00. Experiencing a 10.5% decline, the current average is now lower than the previous average price target of $466.34. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1725969731_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>A clear picture of Ulta Beauty's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anna Glaessgen</td>
<td>B. Riley Securities</td>
<td>Announces</td>
<td>Sell</td>
<td>$300.00</td>
<td>-</td>
</tr>
<tr>
<td>Anthony Chukumba</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$450.00</td>
<td>$520.00</td>
</tr>
<tr>
<td>Michael Baker</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$435.00</td>
<td>$507.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$450.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Kelly Crago</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$345.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>Susan Anderson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$442.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$335.00</td>
<td>$328.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$505.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Simeon Siegel</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$385.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$356.00</td>
<td>$404.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$300.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$385.00</td>
<td>$475.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$395.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Rupesh Parikh</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$435.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Michael Binetti</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$420.00</td>
<td>$430.00</td>
</tr>
<tr>
<td>Olivia Tong</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$450.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Lorraine Hutchinson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$380.00</td>
<td>$425.00</td>
</tr>
<tr>
<td>Krisztina Katai</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$448.00</td>
<td>$552.00</td>
</tr>
<tr>
<td>Susan Anderson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$500.00</td>
<td>$522.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$500.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Michael Binetti</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$430.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Mark Altschwager</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$485.00</td>
<td>$525.00</td>
</tr>
<tr>
<td>Rupesh Parikh</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$450.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Kate McShane</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$412.00</td>
<td>$475.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$325.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$404.00</td>
<td>$494.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$500.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Rupesh Parikh</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$450.00</td>
<td>$475.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$494.00</td>
<td>$498.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$355.00</td>
<td>$394.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Ulta Beauty. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Ulta Beauty compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Ulta Beauty's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Ulta Beauty's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ULTA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Ulta Beauty analyst ratings.</strong></a></p>
<h2>Discovering Ulta Beauty: A Closer Look</h2>
<p>With 1,385 stores at the end of fiscal 2023 and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the US. The firm offers makeup (41% of 2023 sales), fragrances, skin care (19% of sales), and hair care products (19% of sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.</p>
<h3>Ulta Beauty: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Ulta Beauty showcased positive performance, achieving a revenue growth rate of <strong>0.88%</strong> as of 31 July, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Ulta Beauty's net margin is impressive, surpassing industry averages. With a net margin of <strong>9.9%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Ulta Beauty's ROE excels beyond industry benchmarks, reaching <strong>10.87%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>4.44%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.82</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

ULTA

Expert Outlook: Ulta Beauty Through The Eyes Of 30 Analysts

<p>Academy Sports (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) reported quarterly earnings of $2.03 per share which met the analyst consensus estimate. This is a 2.87 percent decrease over earnings of $2.09 per share from the same period last year.  The company reported quarterly sales of $1.55 billion which missed the analyst consensus estimate of $1.57 billion by 1.34 percent.  This is a 2.15 percent decrease over sales of $1.58 billion the same period last year.</p>


Academy Sports Q2 Adj $2.03, Inline, Sales $1.55B Miss $1.57B Estimate

<p><strong>Tesla, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) appears to be on track to extend its gains on Tuesday, buoyed by <a href="https://www.benzinga.com/news/24/09/40785971/teslas-weekly-insurance-registrations-cross-16k-in-china-on-track-for-their-best-quarter-ever-says-b">positive tidings from China.</a></p>
<p>Vehicle insurance registration data for Tesla vehicles came in at a robust 16,200 for the week ended Sept. 8, CnEVPost <a href="https://cnevpost.com/2024/09/10/china-ev-insurance-registrations-week-ending-sept-8-2024/">reported</a>, citing data provided by <strong>Li Auto, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>). This compares to the previous week&#8217;s number of 14,400 units and marked the strongest increase since the 17,500 units reported for the third week of June. </p>
<p>Commenting on the data, Tesla bull and fund manager <strong>Gary Black</strong> said the weekly registration data suggest Tesla is on track to record the best quarter ever. With three weeks left in the quarter, the quarter-to-Sept. 8 data show 15% year-over-year and 25% sequential growth.</p>
<p>Tesla&#8217;s fundamentals have taken a turn for the worse since 2022 amid slowing demand and heightened competition. The sales recovery came amid the company extending its zero-interest financing until the end of the quarter. The next major catalyst for the company is the quarterly delivery numbers, due early October, followed by the Robotaxi Day on Oct. 10.</p>
<p>In premarket trading, Tesla shares rose 1.28% to $219.04, according to <a href="https://benzinga.grsm.io/register174">Benzinga Pro data.</a> On Monday, the stock climbed 2.63% to $216.27, which marks a 13% decline for the year.</p>
<p><em>Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;</em><a href="http://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener"><em>following this link</em></a><em>.</em></p>
<p><strong><em>See Also: <a href="https://www.benzinga.com/money/best-electric-vehicle-stocks">Best EV Stocks</a></em></strong></p>
<p><em>Image via Shutterstock</em></p>


Equities

Movers

Tech

Trading Ideas

TSLA

Tesla Stock Races Higher In Premarket: What's Going On?

Accenture Launches Personalized Experiences On Salesforce Solution That Leverages Data And Artificial Intelligence

<p>4 analysts have expressed a variety of opinions on Honest Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNST#NASDAQ">HNST</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $5.5, with a high estimate of $6.50 and a low estimate of $3.00. This upward trend is evident, with the current average reflecting a 22.22% increase from the previous average price target of $4.50.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1725969716_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Honest Co. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anna Glaessgen</td>
<td>B. Riley Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$6.50</td>
<td>-</td>
</tr>
<tr>
<td>Owen Rickert</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$6.50</td>
<td>$6.00</td>
</tr>
<tr>
<td>Owen Rickert</td>
<td>Northland Capital Markets</td>
<td>Announces</td>
<td>Outperform</td>
<td>$6.00</td>
<td>-</td>
</tr>
<tr>
<td>Laura Champine</td>
<td>Loop Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Honest Co. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Honest Co compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Honest Co's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Honest Co's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/HNST/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Honest Co analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering Honest Co: A Closer Look</h2>
<p>The Honest Co Inc is a digitally-native consumer products company to makes purpose-driven consumer products designed for all people. It is an omnichannel brand, ensuring its products are available wherever its consumers shop through the company's Retail and Digital channels. It has three product categories namely; Diapers and Wipes, Skin and Personal Care, and Household and Wellness, out of which the majority of its revenue is generated from the sale of diapers and wipes. The company operates only in the United States.</p>
<h3>Key Indicators: Honest Co's Financial Health</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Honest Co showcased positive performance, achieving a revenue growth rate of <strong>10.06%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-4.38%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Honest Co's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-3.2%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>-2.05%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Honest Co's debt-to-equity ratio is below the industry average. With a ratio of <b>0.2</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


HNST

Beyond The Numbers: 4 Analysts Discuss Honest Co Stock

<p>Deutsche Bank  analyst Edison Yu   reinstates General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) with a Hold and announces $53 price target.</p>


Price Target

Initiation

Deutsche Bank Reinstates Hold on General Motors, Announces $53 Price Target

<p>Ratings for Blue Bird (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Blue Bird, presenting an average target of $64.8, a high estimate of $72.00, and a low estimate of $54.00. This upward trend is apparent, with the current average reflecting a 10.58% increase from the previous average price target of $58.60.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1725969700_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Blue Bird by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Pierce</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$72.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Michael Shlisky</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$67.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Adam Seiden</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$54.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Sherif El-Sabbahy</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$66.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Chris Pierce</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$52.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Blue Bird. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Blue Bird compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Blue Bird's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Blue Bird's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BLBD/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Blue Bird analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind Blue Bird</h2>
<p>Blue Bird Corp is an American bus manufacturing company. It has its operations in two segments. The Bus segment involves the design, engineering, manufacture and sales of school buses and extended warranties; and the Parts segment which includes the sales of replacement bus parts. It carries its operations in the United States, Canada, and the rest of the world. The majority of its sales are derived from the United States through its bus manufacturing business.</p>
<h3>Understanding the Numbers: Blue Bird's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Blue Bird's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>13.28%</strong> as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>8.61%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Blue Bird's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>23.62%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>6.21%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.71</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BLBD

Beyond The Numbers: 5 Analysts Discuss Blue Bird Stock

<p><strong>Moxy</strong>, known formally as<strong> 5-MeO-MIPT</strong>, is a powerful synthetic psychedelic that has gained momentum in recent years. Initially synthesized in the 1980s, the compound remained relatively obscure until the early 2000s, when interest in psychedelics grew, particularly among those exploring their <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">therapeutic potential.</a> Today, Moxy is becoming increasingly popular among recreational users worldwide, noted for its brief but intense psychedelic experience.</p>
<h3 class="wp-block-heading"><strong>What Is Moxy?</strong></h3>
<p>First synthesized in 1985 by psychedelics pioneers<strong> Alexander</strong> and <strong>Ann Shulgin </strong>and<strong> David B. Repke, </strong>Moxy<strong> </strong>is a synthetic tryptamine, chemically related to serotonin and other psychedelics like <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a> and <a href="https://www.benzinga.com/topic/dmt">DMT</a><strong>. </strong>Its synthesis arose from <a href="https://pubs.acs.org/doi/abs/10.1021/jm00145a007">tests</a> that looked at how small changes in the chemical structure of a drug could influence the effects it produces when consumed<strong>.</strong> Despite its short duration —usually lasting 15 to 45 minutes—Moxy is highly potent, with users typically consuming doses between 2 mg and 10 mg. The experience is characterized by profound perceptual changes, vivid hallucinations and feelings of ego dissolution. Unlike longer-lasting psychedelics like <a href="https://www.benzinga.com/topic/lsd">LSD</a> or psilocybin, Moxy's effects are known for peaking quickly and subsiding within minutes, which can make the experience overwhelming for those unprepared for the intensity.</p>
<h3 class="wp-block-heading"><strong>A Global Trend</strong></h3>
<p>Moxy's global rise can be attributed to the growing interest in psychedelics, both for recreational and therapeutic purposes. In Europe, countries like the United Kingdom, Germany and the Netherlands have seen a steady increase in its use, particularly within psychedelic microdosing circles and those interested in exploring alternative mental health treatments. Early reports indicate that about 5% of psychedelic users in these regions have experimented with Moxy.</p>
<p>In the United States and Canada, the substance has gained a foothold within psychedelic communities. With the broader acceptance of substances like psilocybin and <a href="https://www.benzinga.com/topic/mdma">MDMA</a>, many users are beginning to explore lesser-known psychedelics, including Moxy.</p>
<p>Australia and New Zealand are also seeing the rise of Moxy, though its presence remains limited. In these regions, small communities are experimenting with the compound, and harm reduction organizations are starting to address its use within the broader psychedelic context.</p>
<h3 class="wp-block-heading"><strong>Safety And Harm Reduction</strong></h3>
<p>Given its potency, Moxy poses several safety challenges. The intensity of its effects at low doses increases the risk of psychological distress, particularly for first-time users. As with many psychedelics, Moxy acts on serotonin receptors in the brain, specifically the 5-HT2A receptor, which is responsible for its hallucinogenic properties. This makes Moxy a powerful substance that can trigger profound emotional and cognitive experiences.</p>
<p>Many harm reduction groups emphasize the importance of education around its use. Safe consumption practices, such as <a href="https://www.tripsafely.ca/post/5-meo-mipt-dosage-and-administration-a-guide-to-navigating-your-journey">careful dosing</a>, the presence of a sober trip sitter and using the substance in controlled environments, are essential to mitigating the risks. Additionally, because Moxy is not as widely studied as other psychedelics, its long-term effects are still not fully understood, making harm reduction efforts even more critical.</p>
<h3 class="wp-block-heading"><strong>Legal Landscape</strong></h3>
<p>Moxy's legal status varies widely across the globe. In some countries, it remains in a legal gray area, while in others, it is covered under broad psychoactive substance bans. In the United States, while Moxy is not explicitly scheduled, is listed as a <a href="https://www.benzinga.com/topic/federal-schedule-i">Schedule I</a> controlled substance in the states of <a href="http://leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&amp;URL=0800-0899/0893/0893.html">Florida</a>, <a href="https://www.erowid.org/chemicals/5meo_mipt/5meo_mipt_law.shtml">Louisiana</a> and <a href="https://www.revisor.mn.gov/statutes/?id=152.02">Minnesota</a>. Possession and sale of Moxy for human consumption also remains illegal due to the <a href="https://www.law.cornell.edu/uscode/text/21/813">Federal Analogue Act</a>, which allows authorities to regulate substances similar to already controlled drugs.&nbsp;</p>
<p>Two years ago, the <a href="https://www.benzinga.com/topic/drug-enforcement-administration">Drug Enforcement Administration (DEA)</a> considered classifying moxy and four similar substances as <a href="https://www.benzinga.com/markets/cannabis/22/02/25316205/war-on-drugs-update-dea-to-expand-list-of-banned-psychedelics">high-risk controlled substances</a>. Public pushback prompted the DEA to request a new scientific review, allowing moxy research to continue.</p>
<h3 class="wp-block-heading"><strong>Future Research</strong> And Therapeutic Potential</h3>
<p>Recently, <strong>Mindstate Design Labs</strong> announced that the <a href="https://www.benzinga.com/topic/food-and-drug-administration">Food and Drug Administration (FDA)</a> and the <strong>European Medicines Agency </strong>had <a href="https://www.benzinga.com/markets/cannabis/24/09/40729793/tofu-like-psychedelic-gets-fda-nod-mindstates-ai-designed-therapy-to-begin-human-trials">approved an early-stage clinical trial involving Moxy</a>. This trial will investigate whether the substance can treat mental health conditions such as depression, anxiety and PTSD. </p>
<p>This development is notable in light of recent challenges faced by the psychedelics community. In August, <a href="https://www.benzinga.com/markets/cannabis/24/08/40300943/fda-rejects-mdma-for-ptsd-treatment-calls-for-more-research-on-psychedelic-therapy">the FDA rejected the use of MDMA</a> (commonly known as ecstasy) in combination with talk therapy to treat PTSD, citing concerns over clinical trials conducted by Lykos Therapeutics. Despite this setback, researchers remain optimistic. Interestingly, <strong>David Hough</strong>, a pharmaceutical industry expert now advising Lykos, is also leading Mindstate's Moxy research, indicating continuity in efforts to push psychedelic treatments into mainstream medicine.</p>
<p><em>Cover image made with AI</em></p>


Cannabis

Psychedelics

Moxy: The Short, Intense Psychedelic High Sweeping The Globe

<p>Keybanc  analyst Jason Ader   maintains Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) with a Overweight and raises the price target from $165 to $175.</p>


ORCL

Keybanc Maintains Overweight on Oracle, Raises Price Target to $175

Dividends

IDCC

InterDigital Increases Quarterly Cash Dividend From $0.40 To $0.45 Per Share

KRNT

Kornit Digital Board Authorizes $100M Share Repurchase Program

<p>Across the recent three months, 8 analysts have shared their insights on Calix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $45.0, with a high estimate of $50.00 and a low estimate of $41.00. This upward trend is evident, with the current average reflecting a 10.08% increase from the previous average price target of $40.88.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1725969667_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Calix by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan Koontz</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Ryan Koontz</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Christian Schwab</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$50.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Mike Genovese</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$45.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Ryan Koontz</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Scott Searle</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$44.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Ryan Koontz</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$41.00</td>
<td>$28.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Calix. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Calix compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Calix's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Calix's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CALX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Calix analyst ratings.</strong></a></p>
<h2>About Calix</h2>
<p>Calix Inc develops, market and sell Calix cloud, systems and software platforms to enable service providers of all types and sizes to innovate and transform. The company's customers utilize the real-time data and insights from Calix platforms to simplify their business and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty and revenue creates more value for their businesses and communities. The Company's revenue is principally derived in the United States and it also has its presence in Middle East &amp; Africa, Europe, Asia Pacific and other markets.</p>
<h3>Financial Insights: Calix</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Calix's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately <strong>-24.09%</strong> in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Calix's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-4.02%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Calix's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-1.06%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Calix's ROA excels beyond industry benchmarks, reaching <strong>-0.86%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.01</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CALX

Navigating 8 Analyst Ratings For Calix

<p>In the last three months, 8 analysts have published ratings on Boot Barn Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Boot Barn Holdings, revealing an average target of $143.0, a high estimate of $165.00, and a low estimate of $125.00. This upward trend is apparent, with the current average reflecting a 6.12% increase from the previous average price target of $134.75.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1725969654_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The standing of Boot Barn Holdings among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Janine Stichter</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$165.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$127.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$147.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Jonathan Komp</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>John Lawrence</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$125.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$146.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Steven Zaccone</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$154.00</td>
<td>$122.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Boot Barn Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Boot Barn Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Boot Barn Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Boot Barn Holdings's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BOOT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Boot Barn Holdings analyst ratings.</strong></a></p>
<h2>All You Need to Know About Boot Barn Holdings</h2>
<p>Boot Barn Holdings Inc operates specialty retail stores. The company sells western and work-related footwear, apparel, and accessories in the United States. It is a single operating segment, which includes net sales generated from its retail stores and e-commerce websites.</p>
<h3>Boot Barn Holdings: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Boot Barn Holdings showcased positive performance, achieving a revenue growth rate of <strong>10.34%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>9.19%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Boot Barn Holdings's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>4.04%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Boot Barn Holdings's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>2.24%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Boot Barn Holdings's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.5</strong>.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BOOT

Forecasting The Future: 8 Analyst Projections For Boot Barn Holdings

<ul>
<li>&ndash; New data showed improvements in cognition and behavior during the first year of treatment with additional increases demonstrated as treatment continued &ndash;</li>
<li>&ndash; Clinical effects observed across the Phase 1/2a and open-label extension studies (OLEs) of zorevunersen are a first in the treatment of Dravet syndrome and support plans for the Company&#39;s Phase 3 registrational study &ndash;</li>
<li>&ndash; Zorevunersen generally well-tolerated across the studies &ndash;</li>
<li>&ndash; Data presented for the first time at the 15th European Epilepsy Congress (EEC) &ndash;</li>
</ul>


STOK

Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Seizure Reduction And Cognitive Improvements In Dravet Syndrome

<p>Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) underwent analysis by 24 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $168.42, a high estimate of $192.00, and a low estimate of $124.00. Experiencing a 3.16% decline, the current average is now lower than the previous average price target of $173.92. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1725969619_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The standing of Darden Restaurants among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nick Setyan</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$170.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Brian Vaccaro</td>
<td>Raymond James</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Andrew Charles</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$150.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Brian Mullan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$159.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Jim Salera</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$165.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Nick Setyan</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$170.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Andy Barish</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$124.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>John Staszak</td>
<td>Argus Research</td>
<td>Lowers</td>
<td>Buy</td>
<td>$175.00</td>
<td>$186.00</td>
</tr>
<tr>
<td>Brian Harbour</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Brian Vaccaro</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$170.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Jon Tower</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$192.00</td>
<td>$191.00</td>
</tr>
<tr>
<td>Chris O'Cull</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$180.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Sara Senatore</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$185.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Jim Salera</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$165.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Andrew Charles</td>
<td>TD Cowen</td>
<td>Maintains</td>
<td>Buy</td>
<td>$170.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Jim Salera</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$165.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Nick Setyan</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$170.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Brian Vaccaro</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$167.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Jeffrey Bernstein</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$187.00</td>
</tr>
<tr>
<td>Jim Salera</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$165.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Andrew Charles</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$170.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Sara Senatore</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$180.00</td>
<td>$194.00</td>
</tr>
<tr>
<td>Eric Gonzalez</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$170.00</td>
<td>$177.00</td>
</tr>
<tr>
<td>David Palmer</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$165.00</td>
<td>$170.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Darden Restaurants. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Darden Restaurants compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Darden Restaurants's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Darden Restaurants's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DRI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Darden Restaurants analyst ratings.</strong></a></p>
<h2>About Darden Restaurants</h2>
<p>Darden Restaurants is the largest restaurant operator in the us full-service space, with consolidated revenue of $11.4 billion in fiscal 2024 resulting in 3%-4% full-service market share (per NRA data and our calculations). The company maintains a portfolio of 10 restaurant brands: Olive Garden, LongHorn Steakhouse, Cheddar's Scratch Kitchen, Ruth's Chris, Yard House, The Capital Grille, Seasons 52, Eddie V's, Bahama Breeze, and The Capital Burger. Darden generates revenue almost exclusively from company-owned restaurants, though a small network of franchised restaurants and consumer-packaged goods sales through the traditional grocery channel contribute modestly. As of the end of its fiscal 2024, the company operated 2,031 restaurants in the us.</p>
<h3>Darden Restaurants's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Growth:</strong> Darden Restaurants displayed positive results in 3 months. As of 31 May, 2024, the company achieved a solid revenue growth rate of approximately <strong>6.8%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Darden Restaurants's net margin is impressive, surpassing industry averages. With a net margin of <strong>10.42%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>13.93%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Darden Restaurants's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>2.72%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Darden Restaurants's debt-to-equity ratio is below the industry average. With a ratio of <b>2.42</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Unveiling 24 Analyst Insights On Darden Restaurants

<p>Deutsche Bank  analyst Winnie Dong   reinstates SES AI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) with a Hold and announces $1.5 price target.</p>


Deutsche Bank Reinstates Hold on SES AI, Announces $1.5 Price Target

Adevinta gains amid takeover speculation

EBay confirms that it will support a deal for Adevinta

Oakmark International Small Cap Fund: Q3 2023 And FY-End Commentary

Buyout group reconsiders acquisition of EBay-back Adevinta - report

Private equity firms near €14 Billion deal for eBay-backed Adevinta - report

Private equity firms near €14 Billion deal for eBay-backed Adevinta - (update)

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Adevinta ASA DR

Adevinta ASA DR (ADEVY) Forecast

Adevinta ASA DR (OTC:ADEVY) Stock, Quote.Headers.trade-ideas